XERS - Xeris gets U.K. MHRA approval for hypoglycaemia treatment Ogluo

Xeris Pharmaceuticals (XERS) announces that the United Kingdom’s Medicines and Healthcare Regulatory Agency ((MHRA)) has approved Ogluo (glucagon) injection for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus.The marketing authorization is valid in the United Kingdom, all 27 countries of the European Union, Iceland, Norway, and Liechtenstein.Company reiterated that it is actively seeking a partner to commercialize Ogluo in the U.K., EU, and other regions, with a targeted fourth quarter 2021 launch in select EU countries.Ogluo is indicated for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus.

For further details see:

Xeris gets U.K. MHRA approval for hypoglycaemia treatment Ogluo